NCT00005781 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Albert LS, Rhodes AR, Sober AJ
Dysplastic melanocytic nevi and cutaneous melanoma: markers of increased melanoma risk for affected persons and blood relatives. J Am Acad Dermatol. 1990 Jan;22(1):69-75.
English DR, Menz J, Heenan PJ, Elder DE, Watt JD, Armstrong BK
The dysplastic naevus syndrome in patients with cutaneous malignant melanoma in Western Australia. Med J Aust. 1986 Sep 1;145(5):194-8.
Rigel DS
Malignant melanoma: perspectives on incidence and its effects on awareness, diagnosis, and treatment. CA Cancer J Clin. 1996 Jul-Aug;46(4):195-8. Review.

Digital Imaging as a Tool for Assessing the Prevalence of Atypical Nevi, Psoriasis and Hand Dermatitis: A Validation Study in Preparation for NHANES IV, Dermatology Section

Details for clinical trial NCT00005781

Clinical trial NCT00005781 - References